Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (4): 357-361.doi: 10.35541/cjd.20201117
• Reviews • Previous Articles Next Articles
Wang Ao, Yao Xu
Received:
2020-11-20
Revised:
2020-12-30
Online:
2022-04-15
Published:
2022-04-01
Contact:
Yao Xu
E-mail:dryao_xu@126.com
Supported by:
Wang Ao, Yao Xu. Mechanisms of pruritus in atopic dermatitis[J]. Chinese Journal of Dermatology, 2022, 55(4): 357-361.doi:10.35541/cjd.20201117
[1] | Silverberg JI, Lei D, Yousaf M, et al. Association of atopic dermatitis severity with cognitive function in adults[J]. J Am Acad Dermatol, 2020,83(5):1349⁃1359. doi: 10.1016/j.jaad. 2020.05.041. |
[2] | Kong TS, Han TY, Lee JH, et al. Correlation between severity of atopic dermatitis and sleep quality in children and adults[J]. Ann Dermatol, 2016,28(3):321⁃326. doi: 10.5021/ad.2016.28.3. 321. |
[3] | Wang F, Kim BS. Itch: A Paradigm of neuroimmune crosstalk[J]. Immunity, 2020,52(5):753⁃766. doi: 10.1016/j.immuni. 2020. 04.008. |
[4] | Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2020,34(2):239⁃250. doi: 10.1111/jdv.15973. |
[5] | Gouin O, L', Herondelle K, et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro⁃inflammatory response induced by their activation and their sensitization[J]. Protein Cell, 2017,8(9):644⁃661. doi: 10.1007/s13238⁃017⁃0395⁃5. |
[6] | Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron⁃specific GPCR Mrgprs are itch receptors mediating chloroquine⁃induced pruritus[J]. Cell, 2009,139(7):1353⁃1365. doi: 10.1016/j.cell. 2009.11.034. |
[7] | Azimi E, Reddy VB, Pereira P, et al. Substance P activates Mas⁃related G protein⁃coupled receptors to induce itch[J]. J Allergy Clin Immunol, 2017,140(2):447⁃453.e3. doi: 10.1016/j.jaci.2016. 12.980. |
[8] | Reddy VB, Lerner EA. Activation of mas⁃related G⁃protein⁃coupled receptors by the house dust mite cysteine protease Der p1 provides a new mechanism linking allergy and inflammation[J]. J Biol Chem, 2017,292(42):17399⁃17406. doi: 10.1074/jbc.M117.787887. |
[9] | Meixiong J, Vasavda C, Snyder SH, et al. MRGPRX4 is a G protein⁃coupled receptor activated by bile acids that may contribute to cholestatic pruritus[J]. Proc Natl Acad Sci U S A, 2019,116(21):10525⁃10530. doi: 10.1073/pnas.1903316116. |
[10] | Xing Y, Chen J, Hilley H, et al. Molecular signature of pruriceptive MrgprA3(+) neurons[J]. J Invest Dermatol, 2020,140(10):2041⁃2050. doi: 10.1016/j.jid.2020.03.935. |
[11] | Xie B, Li XY. Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1[J]. J Dermatol, 2019,46(3):177⁃185. doi: 10.1111/1346⁃8138.14749. |
[12] | Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out?[J]. Clin Rev Allergy Immunol, 2016,51(3):263⁃292. doi: 10.1007/s12016⁃ 015⁃8488⁃5. |
[13] | Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch[J]. Cell, 2017,171(1):217⁃228.e13. doi: 10.1016/j.cell.2017.08. 006. |
[14] | Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC⁃14028 cream ⁃ a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild⁃to⁃moderate atopic dermatitis: a phase IIb randomized trial[J]. Br J Dermatol, 2019,180(5):1030⁃1038. doi: 10.1111/bjd.17455. |
[15] | Palkar R, Ongun S, Catich E, et al. Cooling relief of acute and chronic itch requires TRPM8 channels and neurons[J]. J Invest Dermatol, 2018,138(6):1391⁃1399. doi: 10.1016/j.jid.2017.12. 025. |
[16] | Zhao J, Munanairi A, Liu XY, et al. PAR2 mediates itch via TRPV3 signaling in keratinocytes[J]. J Invest Dermatol, 2020,140(8):1524⁃1532. doi: 10.1016/j.jid.2020.01.012. |
[17] | Seo SH, Kim S, Kim SE, et al. Enhanced thermal sensitivity of TRPV3 in keratinocytes underlies heat⁃induced pruritogen release and pruritus in atopic dermatitis[J]. J Invest Dermatol, 2020,140(11):2199⁃2209.e6. doi: 10.1016/j.jid.2020.02.028. |
[18] | Topal FA, Zuberbier T, Makris MP, et al. The role of IL⁃17, IL⁃23 and IL⁃31, IL⁃33 in allergic skin diseases[J]. Curr Opin Allergy Clin Immunol, 2020,20(4):367⁃373. doi: 10.1097/ACI. 0000000000000658. |
[19] | Bilsborough J, Leung DY, Maurer M, et al. IL⁃31 is associated with cutaneous lymphocyte antigen⁃positive skin homing T cells in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2006,117(2):418⁃425. doi: 10.1016/j.jaci.2005.10.046. |
[20] | Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: Involvement of TRPV1 and TRPA1[J]. J Allergy Clin Immunol, 2014,133(2):448⁃460. doi: 10.1016/j.jaci.2013.10.048. |
[21] | Wilson SR, Thé L, Batia LM, et al. The epithelial cell⁃derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013,155(2):285⁃295. doi: 10.1016/j.cell.2013.08. 057. |
[22] | Petra AI, Tsilioni I, Taracanova A, et al. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E[J]. Allergy Asthma Proc, 2018,39(2):153⁃160. doi: 10.2500/aap.2018.38. 4105. |
[23] | Liu B, Tai Y, Achanta S, et al. IL⁃33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy[J]. Proc Natl Acad Sci U S A, 2016,113(47):E7572⁃7572E7579. doi: 10.1073/pnas.1606608113. |
[24] | Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL⁃31⁃induced atopic dermatitis[J]. J Allergy Clin Immunol, 2018,141(5):1677⁃1689.e8. doi: 10.1016/j.jaci.2017.12.1002. |
[25] | Feld M, Garcia R, Buddenkotte J, et al. The pruritus⁃ and TH2⁃associated cytokine IL⁃31 promotes growth of sensory nerves[J]. J Allergy Clin Immunol, 2016,138(2):500⁃508.e24. doi: 10. 1016/j.jaci.2016.02.020. |
[26] | Oh MH, Oh SY, Lu J, et al. TRPA1⁃dependent pruritus in IL⁃13⁃induced chronic atopic dermatitis[J]. J Immunol, 2013,191(11):5371⁃5382. doi: 10.4049/jimmunol.1300300. |
[27] | Singh B, Jegga AG, Shanmukhappa KS, et al. IL⁃31⁃driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin⁃barrier function[J]. PLoS One, 2016,11(8):e0161877[2020⁃09⁃03]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161877. doi: 10.1371/journal.pone.016 1877. |
[28] | Ryu WI, Lee H, Bae HC, et al. IL⁃33 down⁃regulates CLDN1 expression through the ERK/STAT3 pathway in keratinocytes[J]. J Dermatol Sci, 2018,90(3):313⁃322. doi: 10.1016/j.jdermsci.2018.02.017. |
[29] | Ding W, Stohl LL, Wagner JA, et al. Calcitonin gene⁃related peptide biases Langerhans cells toward Th2⁃type immunity[J]. J Immunol, 2008,181(9):6020⁃6026. doi: 10.4049/jimmunol.181. 9.6020. |
[30] | Meng J, Chen W, Wang J. Interventions in the B⁃type natriuretic peptide signalling pathway as a means of controlling chronic itch[J]. Br J Pharmacol, 2020,177(5):1025⁃1040. doi: 10.1111/bph.14952. |
[31] | Kiguchi N, Sukhtankar DD, Ding H, et al. Spinal functions of b⁃type natriuretic peptide, gastrin⁃releasing peptide, and their cognate receptors for regulating itch in mice[J]. J Pharmacol Exp Ther, 2016,356(3):596⁃603. doi: 10.1124/jpet.115.229997. |
[32] | Buhl T, Ikoma A, Kempkes C, et al. Protease⁃activated receptor⁃2 regulates neuro⁃epidermal communication in atopic dermatitis[J]. Front Immunol, 2020,11:1740. doi: 10.3389/fimmu.2020. 01740. |
[33] | Yosipovitch G, Misery L, Proksch E, et al. Skin barrier damage and itch: review of mechanisms, topical management and future directions[J]. Acta Derm Venereol, 2019,99(13):1201⁃1209. doi: 10.2340/00015555⁃3296. |
[34] | Kido⁃Nakahara M, Wang B, Ohno F, et al. Inhibition of mite⁃induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan[J]. Allergy, 2021,76(1):291⁃301. doi: 10.1111/all.14451. |
[35] | Imai Y, Yasuda K, Sakaguchi Y, et al. Immediate⁃type contact hypersensitivity is reduced in interleukin⁃33 knockout mice[J]. J Dermatol Sci, 2014,74(2):159⁃161. doi: 10.1016/j.jdermsci. 2014.01.009. |
[36] | Talagas M, Lebonvallet N, Leschiera R, et al. Keratinocytes communicate with sensory neurons via synaptic⁃like contacts[J]. Ann Neurol, 2020,88(6):1205⁃1219. doi: 10.1002/ana.25912. |
[37] | Kim HS, Yosipovitch G. The skin microbiota and itch: is there a link?[J]. J Clin Med, 2020,9(4). doi: 10.3390/jcm9041190. |
[38] | Seiti Yamada Yoshikawa F, Feitosa de Lima J, Notomi Sato M, et al. Exploring the role of staphylococcus aureus toxins in atopic dermatitis[J]. Toxins (Basel), 2019,11(6). doi: 10.3390/toxins 11060321. |
[39] | Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus δ⁃toxin induces allergic skin disease by activating mast cells[J]. Nature, 2013,503(7476):397⁃401. doi: 10.1038/nature12655. |
[40] | Chiu IM, Heesters BA, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation[J]. Nature, 2013,501(7465):52⁃57. doi: 10.1038/nature12479. |
[41] | Liu T, Xu ZZ, Park CK, et al. Toll⁃like receptor 7 mediates pruritus[J]. Nat Neurosci, 2010,13(12):1460⁃1462. doi: 10.1038/ nn.2683. |
[42] | Liu T, Berta T, Xu ZZ, et al. TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice[J]. J Clin Invest, 2012,122(6):2195⁃2207. doi: 10.1172/JCI45414. |
[43] | Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa 1610020. |
[44] | Nettis E, Ferrucci SM, Ortoncelli M, et al. Use of Dupilumab for 543 adult patients with moderate⁃to⁃severe atopic dermatitis: a multicenter, retrospective study[J]. J Investig Allergol Clin Immunol, 2020:0. doi: 10.18176/jiaci.0641. |
[45] | Guttman⁃Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high⁃affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical Trial[J]. JAMA Dermatol, 2020,156(4):411⁃420. doi: 10.1001/jamadermatol.2020.0079. |
[46] | Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phase III trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3):437⁃449. doi: 10.1111/bjd.19574. |
[47] | Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate⁃to⁃severe atopic dermatitis: results from the double⁃blind, randomized, multicentre, placebo⁃controlled phase III ECZTRA 3 trial[J]. Br J Dermatol, 2021,184(3):450⁃463. doi: 10.1111/bjd.19573. |
[48] | Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate⁃to⁃severe atopic dermatitis and severe pruritus[J]. J Allergy Clin Immunol, 2020,145(1):173⁃182. doi: 10.1016/j.jaci.2019.08.013. |
[49] | Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus[J]. N Engl J Med, 2020,383(2):141⁃150. doi: 10.1056/NEJMoa1917006. |
[50] | Guttman⁃Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16⁃week results from a randomized, placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2020,145(3):877⁃884. doi: 10.1016/j.jaci.2019.11.025. |
[51] | Ferreira S, Guttman⁃Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib[J]. Am J Clin Dermatol, 2020,21(6):783⁃798. doi: 10.1007/s40257⁃020⁃00548⁃6. |
[52] | Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and an open⁃label, long⁃term extension study[J]. J Am Acad Dermatol, 2020,82(4):823⁃831. doi: 10.1016/j.jaad.2019.12.015. |
[53] | Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL⁃3893787 in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019,143(5):1830⁃1837.e4. doi: 10.1016/j.jaci.2018.07.047. |
[54] | Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double⁃blind, placebo⁃controlled, multicenter, parallel⁃group study of a H4 R⁃antagonist (JNJ⁃39758979) in Japanese adults with moderate atopic dermatitis[J]. J Dermatol, 2015,42(2):129⁃139. doi: 10.1111/1346⁃8138.12726. |
[1] | Xiao-Ting SONG Bo Liu Yu-Di CHEN Zuotao. Pathophysiological pathogenesis of rosacea [J]. Chinese Journal of Dermatology, 2022, 55(5): 446-449. |
[2] | Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303. |
[3] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
[4] | Huang Yaxin, He Yuanmin, Huang Shuli, Xiong Xia, Deng Yongqiong. An investigation into clinical significance of serum chitinase 3-like protein 1 in pemphigus vulgaris [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210155-e20210155. |
[5] | Yan Shi, Zhou Xiaoying, Luo Xiaoyan, Ren Faliang, Jiang Wei, Niu Linlin, Wang Hua, Bai Xiaoming. Construction of a Spink5 conditional knockout mouse model and analysis of its phenotype [J]. Chinese Journal of Dermatology, 2022, 55(2): 95-101. |
[6] | Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210130-e20210130. |
[7] | Zhang Haini, Kou Caixia, Liu Jinquan, Zhang Ruihua, Ma Yinni, Zhang Ruili, Wang Qianqiu. Inductive effect of Treponema pallidum on macrophage polarization [J]. Chinese Journal of Dermatology, 2021, 54(8): 688-695. |
[8] | Men Yuehua, Han Huipu, Akade·Alifu, Yao Yifan, Huang Tingting, Kang Jiarui, Wang Tieshan, Zhang Mingbo, Ju Yanjiao, Chu Ming, Wang Yuedan. Characteristics of skin microbiota in an atopic dermatitis-like mouse model induced by 2,4-dinitrochlorobenzene [J]. Chinese Journal of Dermatology, 2021, 54(7): 605-611. |
[9] | Li Yan, Xu Wei, Li Linfeng. Efficacy of topical hydrocortisone butyrate cream combined with a skin cream dressing in the treatment of atopic dermatitis: a randomized, open, controlled clinical study [J]. Chinese Journal of Dermatology, 2021, 54(5): 452-455. |
[10] | Committee on Allergic Diseases, China Dermatologist Association, Atopic Dermatitis Research Center, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. Expert consensus for management of itch in atopic dermatitis [J]. Chinese Journal of Dermatology, 2021, 54(5): 391-396. |
[11] | Yu Miao, Zhang Jing, Chen Yudi, Liu Bo, Song Xiaoting, Liu Jing, Zhang Xue, Zhao Zuotao. Evaluation of reliability, validity and sensitivity of the Chinese version of pruritus-specific quality of life instrument [J]. Chinese Journal of Dermatology, 2020, 53(9): 698-703. |
[12] | Xiang Ruiyu, Li Suo, Feng Suying. Application of pregabalin in dermatology [J]. Chinese Journal of Dermatology, 2020, 53(3): 233-235. |
[13] | Gao Xiaoman, Li Ming, Yang Min, Wen Wei, Sun Kailyu, Chang Jianmin, Fu Yu. Clinical analysis of vulvar lichen simplex chronicus [J]. Chinese Journal of Dermatology, 2020, 53(2): 113-116. |
[14] | Hu Yuqing, Liu Ping, Mu Zhanglei, Zhang Jianzhong . Effect of benvitimod on the proliferation of, inflammatory cytokine secretion by and skin barrier factor production by HaCaT cells [J]. Chinese Journal of Dermatology, 2020, 53(12): 984-991. |
[15] | Guo Zhiwei, Jin Hongzhong. Pruritus in psoriasis: clinical characteristics, pathogenesis and treatment [J]. Chinese Journal of Dermatology, 2020, 53(12): 1029-1032. |
|